Nightstar Therapeutics (NITE) Stock Price, News & Analysis

Company Overview

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $35.22 to $35.53
• 50-Day Range: $25.41 to $25.41
• 52-Week Range: $9.59 to $29.55
• Volume: 3,979 shs
• Average Volume: 185,808 shs
• Market Capitalization: $1.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NITE Stock Analysis - Frequently Asked Questions

How were Nightstar Therapeutics' earnings last quarter?

Nightstar Therapeutics PLC (NASDAQ:NITE) announced its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.13.

When did Nightstar Therapeutics IPO?

Nightstar Therapeutics (NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

What other stocks do shareholders of Nightstar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nightstar Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), OncoMed Pharmaceuticals (OMED), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals (LGND), Neurocrine Biosciences (NBIX) and Sangamo Therapeutics (SGMO).

Company Calendar

• Last Earnings: 11/13/2018
• Today: 9/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NITE
• CIK: 1711675
• Web: www.nightstartx.com
• Phone: 44-20-7062-2777
• Fax: N/A
• Employees: 47
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.89%
• Return on Assets: -27.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.54
• Quick Ratio: 8.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.89 per share
• Price / Book: 5.99

Miscellaneous

• Outstanding Shares: 33,540,000
• Free Float: N/A
• Market Cap: $1.18 billion
• Optionable: Not Optionable
• Beta: 2.84